AxoGen
Developing technologies for peripheral nerve regeneration and repair.
Launch date
Employees
Market cap
€541m
Enterprise valuation
€584m (Public information from Sep 2024)
Share price
$14.56 AXGN
Alachua Florida (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 112m | 127m | 139m | 159m | 185m | 208m | 232m |
| % growth | 5 % | 13 % | 9 % | 15 % | 16 % | 12 % | 12 % |
| EBITDA | (19.8m) | (21.0m) | (25.1m) | (16.3m) | 16.1m | 29.2m | 46.3m |
| % EBITDA margin | (18 %) | (16 %) | (18 %) | (10 %) | 9 % | 14 % | 20 % |
| Profit | (23.8m) | (27.0m) | (28.9m) | (21.7m) | (15.0m) | <1m | 14.2m |
| % profit margin | (21 %) | (21 %) | (21 %) | (14 %) | (8 %) | - | 6 % |
| EV / revenue | 6.4x | 3.1x | 3.0x | 1.9x | 3.1x | 2.8x | 2.5x |
| EV / EBITDA | -36.4x | -18.6x | -16.8x | -18.0x | 35.7x | 19.8x | 12.4x |
| R&D budget | 17.8m | 24.2m | 27.2m | 28.3m | - | - | - |
| R&D % of revenue | 16 % | 19 % | 20 % | 18 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
| N/A | N/A | IPO | |
$12.1m | Post IPO Equity | ||
| N/A | $2.6m | Debt | |
| N/A | $3.7m | Debt | |
| N/A | $3.0m | Debt | |
* | $21.0m | Debt | |
| N/A | $18.0m | Post IPO Equity | |
* | N/A | Debt | |
| N/A | $13.0m | Post IPO Equity | |
$17.5m | Post IPO Equity | ||
* | N/A | $41.0m | Post IPO Equity |
| Total Funding | - | ||
Related Content
Recent News about AxoGen
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.